Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
genomic abnormalities), after salvage therapy, and for patients with secondary AML. Although the use of reduced-intensity conditioning regimens has enabled more patients with high-risk AML to undergo allogeneic HCT, 6 it may also contribute to higher rates of posttransplant relapse. 7 Unfortunately, relapses occur in both high-risk and low-risk patients, and outcomes are generally very poor for patients who experience relapse. 8 Therefore, better post-remission therapies are needed to prevent relapses and improve long-term survival. As such, optimization of therapy post remission represents a major challenge in the treatment of patients with AML, and the role of maintenance therapy has remained somewhat controversial and inadequately tested.
The objectives of this article are to discuss factors that affect relapse in patients with AML, review non-allogeneic HCT postremission strategies, and describe potential new approaches under investigation.
| POST-REMISSION TREATMENT APPROACHES

| Consolidation therapy
The NCCN Guidelines for AML provide recommendations for postremission therapy based on age (<60 or ≥60 years; Table 1 ) and risk of relapse by cytogenetics and molecular abnormalities. 1 Post-remission therapy recommendations from the European LeukemiaNet (ELN) differ somewhat from those of the NCCN. ELN-recommended consolidation therapy is determined by both age (younger patients [18-60/65 years] and older patients [>60/65 years]) and genetic risk (cytogenetic and molecular; Table 1 ). 5 Over the past 12 months, two targeted therapies were approved for use in induction and consolidation therapy for patients with AML: the FLT3 tyrosine kinase inhibitor, midostaurin (see section 2.2), and the antibody-drug conjugate targeting CD33, gemtuzumab ozogamicin. In addition, a liposomal formulation of daunorubicin and cytarabine was approved for induction and consolidation therapy for untreated AML patients with high-risk features.
Gemtuzumab ozogamicin is approved in combination with daunorubicin and cytarabine for the treatment of adults with newly diagnosed AML whose tumors express the CD33 antigen. 9 In the randomized, open-label, phase 3 ALFA-0701 trial (the basis for approval), previously untreated patients aged 50 to 70 years who achieved CR to standard induction therapy, with or without gemtuzumab ozogamicin, received two consolidation courses of daunorubicin, with or without gemtuzumab ozogamicin. Patients with CR who received gemtuzumab ozogamicin had a significantly higher rate of relapse-free survival (RFS) at two years than controls (50.3% vs 22.7%, respectively; P = .0003). 10 In contrast, in the ECOG E1900 randomized phase 3 trial, 307 patients aged 17 to 60 years with AML who achieved CR after induction therapy (daunorubicin + cytarabine) were randomized to intensive consolidation therapy with or without gemtuzumab ozogamicin (single 6 mg/m 2 dose) before autologous HCT. The single dose of gemtuzumab ozogamicin did not demonstrate a disease-free survival (DFS) or OS benefit over control.
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CPX-351, a liposomal formulation of daunorubicin and cytarabine, is approved for adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. 12 In a randomized, open-label, phase 3 trial, patients aged 60 to 75 years with newly diagnosed secondary AML were randomized to receive up to two cycles of induction with CPX-351. This was followed by up to two cycles of CPX-351 consolidation (n = 153), or up to two cycles of conventional cytarabine/daunorubicin 7 + 3 induction, and up to two cycles of 7 + 3 consolidation (n = 156). At a median follow-up of 20.7 months, median OS was significantly longer in the CPX-351 group vs the 7 + 3 group (9.56 vs 5.95 months, respectively; P = .003). 13 
| Maintenance therapy
The role and benefit of maintenance therapy in adult AML were evaluated more than 30 years ago. This was a trial in which patients were randomized to receive either no further therapy, or long-term maintenance chemotherapy following a morphologic CR. Patients who received no further therapy experienced a significantly shorter duration of remission compared with patients who received maintenance chemotherapy. They ultimately relapsed in a median of 4.1 months, whereas patients who received maintenance chemotherapy relapsed in a median of 8.1 months (P ≤ .002, log rank). 14 The role of maintenance therapy was tested in a parallel trial, in which previously untreated patients with AML in CR after induction therapy were randomized to receive consolidation therapy, with or without monthly chemotherapybased maintenance therapy. This was given until relapse or a maximum of 3 years. Patients who received both consolidation and maintenance therapy had significantly better outcomes (median duration of remission of 13 months and 30% continuous remissions at 2.5 years) compared with patients who received consolidation therapy and no maintenance therapy (median duration of remission of 8 months and 17% continuous remissions at 2.5 years); P = .003; Figure 1 ).
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Since these initial observations, a number of regimens have been evaluated as maintenance therapies in patients with AML. In the randomized, double-blind, placebo-controlled phase 3 RATIFY trial, oral midostaurin was added to consolidation therapy with cytarabine and was given as single-agent maintenance therapy. After a median follow-up of 59 months, results showed that midostaurin significantly prolonged OS vs placebo (median, 74.7 months vs 25.6 months, respectively; P = .009), and decreased the risk of death by 22% (P = .009). The 4-year OS rate was 51.4% in the midostaurin group vs 44.3% in the placebo group. Based on these findings, midostaurin is approved by the US Food and Drug Administration (FDA) for the treatment of adults with FLT3 mutation-positive AML in combination with standard cytarabine consolidation. Although a subset of patients in the trial underwent HCT, and trial therapy was discontinued at the time of transplantation, the risk of death was 24.3% lower with midostaurin vs placebo after censoring data from patients who underwent transplantation.
The 4-year OS rate was 63.7% in the midostaurin group vs 55.7% in the placebo group in this subset, which was not statistically significant. 16 The FDA did not approve midostaurin as maintenance therapy because the design of the trial did not allow for determination of the indepen- Patients aged ≥60 y with CR after intensive induction therapy was compared with observation (control) in patients aged ≥60 years.
The patients had AML, or myelodysplastic syndrome (MDS) with excess of blasts and were in CR after ≥2 cycles of intensive chemotherapy. In 115 patients analyzed, maintenance therapy with azacitidine improved 12-month DFS over control (64% vs 42%, respectively; P = .04). After censoring data from patients who received allogeneic HCT, the investigators determined that the 12-month OS rate was 82%
in the azacitidine group and 63% in the control group (P = .209). 21 A phase 2 study with azacitidine (60 mg/m 2 × 5 days every 28 days as maintenance therapy initiated within 28 days of CR to standard induction chemotherapy) was conducted. The study had 23 patients aged ≥60 years with high-risk MDS, or AML following MDS, and showed no DFS or OS benefit. 22 Also, assessment of survival with decitabine (20 mg/m 2 × 5 days every 6 weeks for 8 cycles) in patients aged <60 years with AML in CR after consolidation therapy showed no benefit in terms of DFS and OS when compared with historical controls. 23 Thus, the use of maintenance therapy remains controversial.
A 2016 systematic literature review of 50 studies assessed the available evidence for the use of maintenance therapy after consolidation therapy or HCT. 24 At the time of publication, the authors did not recommend maintenance therapy after adequate induction and consolidation therapy or after allogeneic HCT, with the exceptions of clinical trial investigation and the use of midostaurin for induction, consolidation, and maintenance therapy in FLT3-mutated AML (although, as mentioned previously, the FDA did not approve midostaurin for maintenance therapy). One reason was the inability to make definitive conclusions regarding the benefits of maintenance therapy, based on data from older trials using induction and consolidation regimens that are no longer standard; (Other reasons included) missing details from those trials and alternative designs used in those trials. Also noted was the lack of randomized studies demonstrating the efficacy of maintenance therapy after allogeneic HCT. 24 Nevertheless, maintenance therapy in patients with AML after remission remains an active area of investigation (discussed below).
| Post-HCT relapse prevention
HCT is recommended after induction failure, residual disease, or as post-remission therapy in properly selected patients. 1 HCT after first CR can improve the prognosis of patients with AML; however, the possibility of relapse-the leading cause of treatment failure-is significant. 25, 26 Furthermore, relapse after HCT is associated with poor outcomes. 27 Thus, strategies to avoid relapse following HCT are needed.
Hypomethylating agents, the most commonly used non-targeted therapies in patients who relapse after HCT, may be effective in with a 14-day regimen. Estimated 1-year survival rates were 86% and 81%, respectively. 31 For patients with FLT3-ITD AML, many FLT3 tyrosine kinase inhibitors are under investigation for post-HCT maintenance, including sorafenib, midostaurin, quizartinib, crenolanib, and gilteritinib. In an early-phase study of 22 patients with FLT3-ITD AML treated with sorafenib following HCT, PFS and OS rates at 1 year were 85% and 95%, respectively. 32 In a retrospective analysis, patients with FLT3-ITD AML treated with sorafenib maintenance after HCT during the first CR (n = 26) were compared with matched patients who were not treated with sorafenib (n = 55). The treated patients showed significantly improved 2-year OS (81% vs 62%, P = .029), PFS (82% vs 53%, P = .0081), and a lower relapse rate (8.2% vs 37.7%, P = .0077) compared with patients not treated with sorafenib. 33 Midostaurin maintenance was investigated in a phase 2 trial that included 40 patients with newly diagnosed FLT3-ITD AML post HCT.
The trial showed a low incidence of relapse in patients with both high and low FLT3-ITD mutant to wild type ratio (5% and 12%, respectively). 34 A randomized, open-label, phase 2 exploratory trial (RADIUS) compared midostaurin in combination with standard of care vs standard of care in newly diagnosed patients (n = 60) with FLT3-ITD AML who were in first CR after HCT. 35 The addition of midostaurin resulted in a 46% relative reduction in the risk of relapse at 18 months. There were estimated relapse rates of 11% and 24% in the midostaurin/standard of care and standard of care groups, respectively; median relapse-free survival was not reached at 18 months, and follow-up is ongoing.
A randomized, double blind, placebo-controlled study (SORMAIN) compared sorafenib maintenance vs placebo in patients (n = 83), with FLT3-ITD AML in complete hematologic remission after HCT. 36 At a median follow up of 41.8 months after randomization, median relapsefree survival was 30.9 months in the placebo group vs not reached in the sorafenib group. This corresponded to a 2-year relapse-free survival rate of 53% with placebo vs 85% with sorafenib (P = .0135).
Quizartinib was evaluated as maintenance therapy in patients (n = 13) with CR post HCT in a phase 1 study; nine patients survived for at least 50 weeks and 4 patients survived for more than 2 years. 6-68 years) showed MRD in the peripheral blood after two cycles of intensive chemotherapy was highly prognostic for death, with a hazard ratio (95% CI) of 4.84 (2.57-9.15; P < .001). The 5-year OS rate was 73% in MRD− patients and 24% in MRD+ patients (P < .001). Furthermore, no significant benefit of HCT was observed in MRD+ patients in this study, although the number of patients analyzed was small. 40 In a recent study, targeted NGS carried out during CR to induction therapy in patients with AML frequently detected persistent mutations in DTA genes (DNMT3A, TET2, ASXL1), which are associated with age-related clonal hematopoiesis. These mutations did not correlate with an increased risk of relapse based on 4-year relapse rates; however, coexisting persistent non-DTA mutations in patients with persistent DTA mutations were highly prognostic for relapse (P = .002). In addition, the persistence of non-DTA mutations among all patients was associated with an increased risk of relapse (P = .001), reduced RFS (P = .006), and reduced OS (P = .01). 41 Recently, NGS-MRD monitoring in AML was shown to be predictive for post-transplant relapse and survival when used in patients with CR prior to allogeneic HCT, 42 and to be prognostic for relapse and mortality when used in patients on day 21 after allogenic HCT. 43 Although MRD negativity is highly prognostic for outcomes in AML, 44 until recently, a drawback to the use of MRD monitoring was that there was no consensus on determining MRD. Lack of standardization and lack of established cutoff values had limited the widespread use of MRD to guide treatment. 1 In March 2018, however, flow cytometric, molecular, and clinical MRD recommendations made by consensus of an international panel of experts were published. 44 Moving forward, these recommendations should provide uniform guidance for the use of MRD to optimize outcomes in AML.
While the prognostic value of MRD is clear, current definitions of CR do not account for MRD, and there are no clear guidelines on how to manage high-risk patients once they are identified. The impact of MRD on survival was assessed in 359 patients (median age at HCT, 50 years; range, 18-75 years) in MRD+ CR, MRD− CR, or with active AML before allogeneic HCT. After transplant, the estimated 3-year OS rate of the 76 MRD+ patients (26%) was similar to that of the 48 patients with active AML (23%), whereas the estimated 3-year OS rate of the 235 MRD-patients was 73%. Multivariable hazard ratio (95% CI) for death was 3.69 (2.51-5.42) for patients with MRD+ status (P < .001) and 4.40 (2.56-7.55) for patients with active AML (P < .001). 45 These results highlight the prognostic importance of MRD and suggest that morphology-based assessments of CR alone are not ideal. 45 In an ongoing phase 2 study (RELAZA2), preemptive treatment with 6 cycles of azacitidine (75 mg/m 2 × 7 days) and MRD risk-adapted treatment for up to 18 additional months was evaluated.
This was done in patients aged ≥18 years with MRD while in CR after conventional chemotherapy only, or consecutive allogeneic HCT. Preemptive MRD risk-adapted treatment prevented or substantially delayed disease relapse in 31 of 53 patients who were still in CR after 6 months (58%; 95% CI: 44-72; P < .001). 46 These results are encouraging; however, future evaluation is needed to identify effective strategies for MRD+ patients.
| Future directions: post-remission therapies under investigation
Selected studies evaluating maintenance therapies in patients with AML are summarized in Table S1 . Hypomethylating agents under investigation as maintenance therapies in AML include guadecitabine (SGI-110) and CC-486, an oral formulation of azacitidine. Guadecitabine achieved a composite complete response that ranged from 50% to 59%
(depending on schedule used) in treatment-naive patients with AML aged ≥65 years in a randomized, open-label, phase 1/2 study. showed a trend for improvement with sorafenib; it was 61% with sorafenib vs 50% with placebo. 55 In contrast, dasatinib did not improve DFS when used as single-agent maintenance therapy in a phase 2 study in 26 patients (7 with KIT mutations; 6 with FLT3 mutations; aged 18-60 years) with core binding factor-AML in first CR. 18-month OS rates of 86% and 67%, respectively; the regimen is well tolerated. 57 Nivolumab is also under investigation in an ongoing ran- CR1 or CR >1 and randomized to receive combination therapy or no treatment. 60 Combination therapy was tolerable and significantly improved leukemia-free survival vs no treatment ≥3 years after the last patient was enrolled. This was true for all patients (34% vs 24%, respectively; P < .01) and for the subset of patients in CR1 at randomization (40% vs 26%, respectively; P < .01).
The effects of addition or no addition of the androgen norethandrolone to maintenance therapy with mercaptopurine and methotrexate, during the post-induction phase, was investigated in a randomized phase 3 study in 325 elderly patients (median age, 70 years) with AML. 61 All patients received induction therapy with idarubicin, cytarabine, and lomustine. Addition of norethandrolone at 20 mg/day to maintenance therapy for 2 years improved the 5-year DFS rate (31.2% vs 16.2%; P = .002), EFS rate (21.5% vs 12.9%; P value not provided), and OS rate (26.3% vs 17.2%; P = .008) compared with no addition of norethandrolone.
| CONCLUSIONS
New strategies are needed to prolong remission and improve survival in patients with AML after CR with induction therapy. Traditional consolidation strategies include the use of single-agent IDAC or HiDAC or cytarabine-based consolidation regimens, continuing with the same induction regimen that achieved CR, or using allogeneic HCT. 1 Emerging data suggest that targeted therapy and combinations of chemotherapy and targeted agents may improve outcomes. Research regarding the benefits of maintenance therapy in patients with AML has been inconclusive to date. However, trials to evaluate new agents and new combination therapies as maintenance therapy, including for the prevention of relapse after HCT, are in progress. In addition, given the known heterogeneity of AML, an important goal moving forward is to identify predictive biomarkers of response to specific maintenance therapies. The ultimate goal is to identify regimens that will prolong survival in patients with AML by achieving and maintaining the best response for as long as possible.
